Skip to content

LOR

Active Private limited companyfounded 2023active for 3 yearsRue Guy de Bres 41, 7000 MonsKBO/BCE: BE 0802.696.576

Lifetime

3 annual accounts with figures on one time axis
peak of €244,089 in 2024
€234,784▼ 3.8%
peak of €164,112 in 2024
€129,249▼ 21.2%
peak of €296,861 in 2025
€296,861▲ 21.3%
€464,199▲ 493%
Board2 names since 2023
2 directors and 1 other
Documentsfilings and deeds
20-07-202611 days before the deadline
2025micro format
Company renamed from Dr Loquette to LOR 09-10Dividend €77,139Equity from €244,751 to €296,861Debts from €78,238 to €464,199Investments €307,847Cash from €270,037 to €386,314

Key points

from the 2025 annual accounts

Equity

€296,861 ▲ 21.3%
244,7512024+129,249Profit-77,139Dividend296,8612025

LOR paid out €77,139 in dividends. That is 60% of the 2025 profit.

Turnover

≈ €420,000 estimated

The micro format states no turnover.

Debts

€464,199 ▲ 493%
Taxes and wages
+75,761
Suppliers
+2,786
The rest
+307,414

Debts rose by €385,961 in 2025.

Investments

€320,957 6.8 times depreciation
202320242025

Green is investment, beige is depreciation.

Liquidity

2.09 was 3.86 in 2024

Short-term debts rose from €78,061 to €229,126.

Position in the sector

€761,061

Larger balance sheet than 81% of companies in human health. Sector median €277,522 · 21,347 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 3,137 companies had the same profile as LOR has now. Each dot stands for 8 companies, two years later.

96.9%
were still trading
2.1%
stopped another way
0.8%
went bankrupt
  • Small
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,912 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 3,137 companies, not a prediction for LOR. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director, since 01-04-2024
  • all the sharesdeed of 23-04-2024
  • 50 sharesdeed of 23-04-2024
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0802696576
Company renamed from Dr Loquette to LOR Registered office moved to Mons · The registered office moved to rue Guy de Brès, numéro 41, 7000 Mons · General meeting of 02-10-2025 · Gazette deed
Transfer of 50 shares from to appointed as director · holds all the shares · General meeting of 20-03-2024 · Gazette deed
Incorporation Founding capital of €3,500, 100 shares · Founded by · appointed as director · published on 15-06-2023 · Gazette deed
All 10 events

Comparable companies

same main activity, similar in size and age
Company
LOR Mons €761,061 €234,784 39.0% -
Dr. Kim De Muynck, huisarts Kaprijke €700,717 €241,141 49.9% -
AMALYMA Dilbeek €844,766 €218,510 28.9% -
DECOUMED Charleroi €672,912 €243,665 58.9% -
Docteur Silon Aurélie Seneffe €710,361 €250,874 38.7% -
CMB-Med Charleroi €574,006 €245,955 60.5% -
HN Medical Colfontaine €550,279 €253,240 76.3% -

These companies have the same main activity as LOR: general medical practice (NACE 86210). They are comparable in size and age: total assets between €550,000 and €845,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 13-06-2023Normal situation
Activity
General medical practiceNACE 86210
Establishment unit
2.346.466.7217000 Mons, since 13-06-2023
Financial year end
31 December
Peppol
Reachable since 20-12-2025
Company details

Annual accounts 2025

€761,061▲ 136%
Filing
Filed on 20-07-2026, 11 days before the end of the filing period
Financials

Insights on LOR

LOR files the micro format. That format states no turnover. The gross margin rose from €102,451 in 2023 to €234,784 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about LOR

What is the company number of LOR?
The company number of LOR is 0802.696.576. The VAT number is the same number with BE in front: BE 0802.696.576.
Where is LOR based?
The registered office is at Rue Guy de Bres 41, 7000 Mons.Company details
What does LOR do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of LOR?
LOR is a private limited company (BV).
When was LOR founded?
LOR was founded on 13-06-2023.
Is LOR still active?
Yes, LOR is an active enterprise in the KBO register.
What is the turnover of LOR?
The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €234,784 and 30 comparable companies (NACE 86210). It probably lies between €340,000 and €530,000.Financials
Is LOR profitable?
In financial year 2025, LOR made a profit of €129,249.
Where can I find the annual accounts of LOR?
LOR filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of LOR due?
LOR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.